Stock Price Prediction

ZLAB stock is currently trading at $27.50. The bull's view is driven by its recent FDA Orphan Drug Designation for ZL-1310, which enhances its oncology pipeline and positions it for long-term growth. Additionally, its strategic collaboration with MediLink Therapeutics for ZL-6201 strengthens its innovative drug portfolio, making it a promising investment in the biotech sector.

ZLAB stock currently trades at $25.50, with bearish sentiment due to its high R&D expenses and delayed revenue realization from its oncology pipeline. Despite promising developments like ZL-6201 and ZL-1310, the lack of near-term catalysts and profitability concerns weigh on the stock. A break below $24 could signal further downside.

The market consensus for ZLAB's revenue in the upcoming quarter is projected to be approximately $116.226M USD.

The market consensus for ZLAB's eps in the upcoming quarter is projected to be approximately $0.59 USD.